ADJUNCTIVE THERAPY OF COMMUNITY-ACKUIRED PNEUMONIA: NECESSITY AND SUFFICIENCY

Objective: analysis of pathogenetic and  symptomatic therapy of community-acquired pneumonia in the prehospital and at the stage  of hospital treatment of disease in hospitals of city Khujand of the Republic of Tajikistan.

Materials and  methods: A retrospective analysis of 393 case  histories of  patients treated for  community-acquired pneumonia in  the  hospital Khujand from  2011  to  2015  is conducted. The estimation of the scope  and efficiency of the additional medical support for the treatment of communityacquired pneumonia was conducted, take  into  account the drugs  that  given  to patients in an outpatient setting and  in a hospital. Analyzed purpose rationale, adequacy of dose, duration of treatment and  compliance of the  activities with existing international and  national guidelines for the treatment  of community-acquired pneumonia.

Results:  the  study found that  in  clinical  practice, 57% of  patients with  community-acquired pneumonia received funds pathogenetic and  symptomatic therapy. It  is  found that  quite  often  prescribed drugs  with  unproven efficiency. Thus,  75%  of patients received expectorants and  mucolytic drugs,   42.2% of  patients  received anti-allergic medicals. Non-steroidal anti-inflammatory medicals received 37.9% of patients with  community-acquired pneumonia, almost  30% of patients receiving infusion therapy. Quite often  (15.7%) patients with   community-acquired  pneumonia  prescribed antifungal drugs  and  antiprotozoal drug  – metronidazole (59%  of cases).  Furthermore, in complex treatment of community-acquired pneumonia include vitamin C (23.1%) and vitamin B (65.9%).

1. Berezniakov I.G., Bogun L.V. Provisor. 2003; 2: 18-22 (in Russian).

2. Bogun L.V. Klinicheskava antibiotikoterapia. 2008; 5: 5-11 (in Russian).

3. Erohin V.V., Romanova L.K. Cell biology of lung in health and disease: a Guide for Physicians. Moscow: Medicine; 2000 (in Russian).

4. Muradov A.М., Yakubov M.R. Vestnik poslediplomnogo obrazovania v sfere zdravoohraneniya. 2013; 3: 21-30 (in Russian).

5. Nasonov E.L. Nonsteroidal anti-inflammatory drugs. Prospects for application in medicine. Moscow: Medicine; 2000 (in Russian).

6. «Negospitalna ta nozokomialna (gospitalna) pnevmonia y dorosluh ocib: etioligia, patogenez, klasfikacia, diagnoctika, antibakterialna terapia». Кiev: Veres; 2012 (in Ukrainian).

7. Rachina S.А., Kozlov R.S., Chal E.V., Nedorozenuk I.V. Arhiv vnutrenney medicine. 2015; 3: 63-74 (in Russian).

8. Smolenov I.V., Alekseeva Y.G., Smirnov N.A. Klinicheskaya mikribioljgia I antimilrobnaya himioterapia. 2002; 4: 45-49 (in Russian).

9. Fuhtey I.M., Savchenko O.A., Podsevahina S.L., Tkachenki O.V. Svit medicine ta biologii. 2015; 1(48): 85-88 (in Russian).

10. Fuhtey I.M., Savchenko O.A., Vitohina L.I. Фуштей И.М. Zaporozskiv medicinskiy zhurnal. 2011; 3: 58-60 (in Russian).

11. Chubukova O.A. Sovershenstvovanie epidemiologicheskogo i mikrobiologicheskogo monitoringa v sisteme epidemiologicheskogo nadzora za vnebolnichnyimi pnevmoniyami [Improving epidemiological and microbiological monitoring of the system of surveillance for community-acquired pneumonia] [avtoref. dis….kand. med. nauk]. Nizhniy Novgorod, 2012. 26р (in Russian).

12. Chuchalin A.G. Sinopalnikov A.I., Strachunskiy L.S. Community-acquired pneumonia in adults: practical recommendations for diagnosis, treatment and prevention. Moscow, «Borges»; 2008 (in Russian).

13. Bartlett J., Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America / J.Bartlett, S. Dowell, L.Mandell [e.a] // Clin. Infect. Dis 2000.Vol. 31.P. 347-382.

14. Bonetti P.F. Ambroxol plus amoxicillin versus amoxicillin alone in various respiratory tract infections / P.F.Bonetti // Invest. Med. Internacional. – 1993. – Vol. 20. – P. 99-103.

15. Chalmers J. C-reactive protein is an independent predictor of severity in community-acquired pneumonia / J.Chalmers, A.Singanayagam., A.Hill // Am. J. Med.2008 – Vol. 121.-P. 219-25.

16. Fujiki R. The risk factors for mortality of community acquired pneumonia in Japan / R. Fujiki [et al.] // J. infect. chemother. – 2007. – Vol. 13, № 3. – P. 157–165.

17. Perneger T.V. Risk of kidney failure associated with the use of acetominophen, aspirin, failure associated with the use of acetaminophen, aspirin and nonsteroidal antiflamatori drugs / T.V. Perneger, P.K. Whelton, M.J.Klag // N. Engl. J. Med. – 1994. – Vol. 331. – P. 1675–1712.

18. State Committee on Statistics. Health and health care in the Republic of Tajikistan in 2007 / Dushanbe, State Committee on Statistics. – 2008. – Р.344.